{"title":"In Silico Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia","authors":"M. H. Elias, Noraziah Nordin, N. A. Hamid","doi":"10.2174/1875692118666200106113610","DOIUrl":null,"url":null,"abstract":"\n\nChronic Myeloid Leukaemia (CML) is associated with the BCRABL1\ngene, which plays a central role in the pathogenesis of CML. Thus, it is crucial to\nsuppress the expression of BCR-ABL1 in the treatment of CML. MicroRNA is known to\nbe a gene expression regulator and is thus a good candidate for molecularly targeted therapy\nfor CML.\n\n\n\n This study aims to identify the microRNAs from edible plants targeting the 3’\nUntranslated Region (3’UTR) of BCR-ABL1.\n\n\n\nIn this in silico analysis, the sequence of 3’UTR of BCR-ABL1 was obtained\nfrom Ensembl Genome Browser. PsRNATarget Analysis Server and MicroRNA Target\nPrediction (miRTar) Server were used to identify miRNAs that have binding conformity\nwith 3’UTR of BCR-ABL1. The MiRBase database was used to validate the species of\nplants expressing the miRNAs. The RNAfold web server and RNA COMPOSER were\nused for secondary and tertiary structure prediction, respectively.\n\n\n\nIn silico analyses revealed that cpa-miR8154, csi-miR3952, gma-miR4414-5p,\nmdm-miR482c, osa-miR1858a and osa-miR1858b show binding conformity with strong\nmolecular interaction towards 3’UTR region of BCR-ABL1. However, only cpa-miR-\n8154, osa-miR-1858a and osa-miR-1858b showed good target site accessibility.\n\n\n\nIt is predicted that these microRNAs post-transcriptionally inhibit the BCRABL1\ngene and thus could be a potential molecular targeted therapy for CML. However,\nfurther studies involving in vitro, in vivo and functional analyses need to be carried out to\ndetermine the ability of these miRNAs to form the basis for targeted therapy for CML.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"4 1","pages":"125-132"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692118666200106113610","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1
Abstract
Chronic Myeloid Leukaemia (CML) is associated with the BCRABL1
gene, which plays a central role in the pathogenesis of CML. Thus, it is crucial to
suppress the expression of BCR-ABL1 in the treatment of CML. MicroRNA is known to
be a gene expression regulator and is thus a good candidate for molecularly targeted therapy
for CML.
This study aims to identify the microRNAs from edible plants targeting the 3’
Untranslated Region (3’UTR) of BCR-ABL1.
In this in silico analysis, the sequence of 3’UTR of BCR-ABL1 was obtained
from Ensembl Genome Browser. PsRNATarget Analysis Server and MicroRNA Target
Prediction (miRTar) Server were used to identify miRNAs that have binding conformity
with 3’UTR of BCR-ABL1. The MiRBase database was used to validate the species of
plants expressing the miRNAs. The RNAfold web server and RNA COMPOSER were
used for secondary and tertiary structure prediction, respectively.
In silico analyses revealed that cpa-miR8154, csi-miR3952, gma-miR4414-5p,
mdm-miR482c, osa-miR1858a and osa-miR1858b show binding conformity with strong
molecular interaction towards 3’UTR region of BCR-ABL1. However, only cpa-miR-
8154, osa-miR-1858a and osa-miR-1858b showed good target site accessibility.
It is predicted that these microRNAs post-transcriptionally inhibit the BCRABL1
gene and thus could be a potential molecular targeted therapy for CML. However,
further studies involving in vitro, in vivo and functional analyses need to be carried out to
determine the ability of these miRNAs to form the basis for targeted therapy for CML.
期刊介绍:
Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.